期刊文献+

高脂血症患者C-反应蛋白的水平及立普妥对血脂和C-反应蛋白的影响 被引量:15

Level of C-reactive protein and effects of lipitor on C-reactive protein and lipids in patients with hyperlipidemia
下载PDF
导出
摘要 目的 :了解高脂血症患者血清中 C-反应蛋白 (CRP)变化并观察立普妥 (lipitor)的降脂作用及对 CRP的影响。方法 :测定 4 2例高脂血症患者和 30例健康者血清中 CRP;高脂血症患者服用立普妥治疗 8周后再次检测血脂和 CRP。结果 :高脂血症患者血清中 CRP明显高于对照组 (P<0 .0 5 ) ;应用立普妥治疗 8周后 ,血清总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白 (L DL)及 CRP明显下降 (P<0 .0 5或 P<0 .0 1 )。结论 :高脂血症患者伴有血清中炎性标记物 CRP的增高 ;立普妥不但能够有效地调节血脂 ,还明显地减轻高脂血症患者的血管炎症反应。 Objective To investigate the C reactive protein(CRP)level and observe the efficacy of lipitor on the lipids and CRP in the patients with hyperlipidemia. Methods The serum CRP was measured in 42 patients with hyperlipidemia and 30 healthy subjects; The lipids and CRP were measured again in patients with hyperlipidemia after 8 weeks of lipitor treatment. Results The serum CRP was obviously higher in hyperlipidemia patients than that in the subjects( P <0 05); After 8 weeks lipitor treatment, TC,TG,LDL, and CRP were decreased significantly ( P <0 05 or P <0 01). Conclusion The inflammation marker CRP is increased in the patients with hyperlipidemia; lipitor may not only largely mediate lipids but also decrease vascular inflammation reaction in patients with hyperlipidemia.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2004年第1期114-116,共3页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅资助课题 (95 30 1 1 ) 吉林省卫生厅医学科研基金资助课题 (2 0 0 2 0 4 5 )
关键词 立普妥 高脂血症/血液 高脂血症/药物疗法 C一反应蛋白/分析 lipitor hyperlipidemia/blood heperlipidemia/drug therapy C reactive protein/analysis
  • 相关文献

参考文献7

  • 1[1]Alexander RW.Inflammation and coronary artery disease [J].N Engl J Med,1994,331:468-469.
  • 2[2]Torzewski J,T orzewski M,Bowyer DE,et al.C-reative protein frequently colocalizes with the terminal comlement complex in the intima of early atherosclerotic lesions of human coronary arteries [J].Arterioscler Thromb Vasc Biol,1998,18:1386-1392.
  • 3[3]Reynolds GD,Vance RP.C-reative protein immunohistochemical localization in normal and atherosclerotic human aortas [J].Arch Pathol Lab Med,1987,111:26.
  • 4[4]Blake GJ,Ridker PM.Novel clinical markers of vascular wall inflammation [J].Circ Res,2001,89(9):763-771.
  • 5[5]Arz W,Wieland H.HMG-CoA reductase inhibition:antiinflammation effects beyond lipid lowering [J].Herz,2000,25(2):117-125.
  • 6[6]Riesen WF,Engler H,Risch M,et al.Short-term effects of atorvastatin on C-reactive protein [J].Eur Heart J,2002,23:794-799.
  • 7[7]Garlichs CD,John S,Schmeisser A,et al.Upregulation of CD40and CD40 ligand(CD154)in patients with moderate hypercholesterolemia [J].Circulation,2001,104(20):2395-2400.

同被引文献92

引证文献15

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部